Alzamend Neuro, Inc. (ALZN)

Alzamend Neuro Income Statement

Financials in millions USD. Fiscal year is May - April.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jan 31, 2025	Apr 30, 2024	Apr 30, 2023	Apr 30, 2022	Apr 30, 2021	Apr 30, 2020
Selling, General & Admin	3.06	3.48	7.42	7.12	3.64	3.35
Research & Development	1.15	6.46	7.45	5.2	1.31	1.07
Operating Expenses	4.21	9.94	14.87	12.32	4.95	4.42
Operating Income	-4.21	-9.94	-14.87	-12.32	-4.95	-4.42
Interest Expense	-0.02	-0.01	-0.01	-0.05	-0.16	-
Interest & Investment Income	-	-	-	-	0	0.01
EBT Excluding Unusual Items	-4.23	-9.95	-14.88	-12.37	-5.11	-4.41
Other Unusual Items	-	-	-	0	0.06	-
Pretax Income	-4.23	-9.95	-14.88	-12.36	-5.05	-4.41
Net Income	-4.23	-9.95	-14.88	-12.36	-5.05	-4.41
Net Income to Common	-4.23	-9.95	-14.88	-12.36	-5.05	-4.41
Shares Outstanding (Basic)	3	1	1	1	0	0
Shares Outstanding (Diluted)	3	1	1	1	0	0
Shares Change (YoY)	294.83%	4.07%	9.46%	22.64%	1.96%	21.09%
EPS (Basic)	-1.61	-14.70	-22.89	-20.81	-10.42	-9.28
EPS (Diluted)	-1.61	-14.70	-22.89	-20.81	-10.42	-9.28
Free Cash Flow	-7.4	-8.42	-8.92	-6.72	-2.71	-2.35
Free Cash Flow Per Share	-2.81	-12.44	-13.72	-11.31	-5.60	-4.94
EBITDA	-4.16	-9.89	-14.85	-12.32	-	-
D&A For EBITDA	0.05	0.05	0.02	0	-	-
EBIT	-4.21	-9.94	-14.87	-12.32	-4.95	-4.42

Updated Mar 10, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q